Pharmacy board advances modified central‑fill rule; opens new 45‑day comment period
Loading...
Summary
The California State Board of Pharmacy voted to accept staff responses and modified text to its proposed central‑fill regulation (Title 16 §1707.4), authorized another 45‑day public comment period, and delegated authority to the executive officer to adopt the rule if no adverse comments are received.
The California State Board of Pharmacy voted on Jan. 26 to advance modified regulatory language for central‑fill pharmacies and to begin another 45‑day public comment period. Member Maria (mover) read a motion accepting staff’s recommended responses to stakeholder comments and authorizing the executive officer to complete the rulemaking and adopt the proposed text at Title 16, section 1707.4 if no adverse comments are received; Ricardo seconded the motion and the board approved it by roll call.
The rulemaking package — which the cover memo says was revised to clarify how a central‑fill model differs from mail‑order pharmacy operations — was the product of committee review and a 45‑day public comment period that ran Oct. 17, 2025, through Dec. 1, 2025. Members debated whether notification to patients that their prescription was filled at a central‑fill location should allow ‘electronic’ notice (for example, text or email) in addition to written notice. Member Maria raised concerns that some patients lack electronic access; other board members and staff said electronic notice (staff confirmed this includes text messaging) increases flexibility and reduces paper waste. After discussion, the board left the proposed language permitting electronic notification in place.
During the public‑comment portion, Laurie Wamsley, speaking for Walgreens, asked the board to permit central‑fill facilities to be located out of state under the board’s authority to regulate nonresident pharmacies and to inspect such facilities. Industry representative Steven Gray, who said he opened the first central‑fill facility for Kaiser Permanente, urged the board to keep in mind that an older rule (referenced in the discussion as 17 13(a)) separately governs where a prescription may be sent for patient pickup and does not replace the central‑fill regulation.
The motion passed on roll call after members recorded affirmative votes (Renee, Jeanette, Jeff, KK, Claudia, Jay, Ricardo, Satinder, Maria and President Seung Oh). The board’s action authorizes staff to issue a revised 45‑day public comment period; if no adverse comments are received, the executive officer is authorized to finalize the rulemaking and make technical or non‑substantive changes required by control agencies.
Next steps: staff will post the modified regulatory text and open the new 45‑day comment period; the executive officer may complete adoption if no adverse comments arrive during that period.
